Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA) - Wells, SA; Robinson, BG; Gagel, RF (J Clin Oncol, 2010)
abstr. 5503.